Category Archives: 2026

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS

AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development

08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer

AB Science announces the successful completion of a EUR 2.3 million private placement

01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors

AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML

29/06/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the completion of Step 3, evaluating the combination of AB8939 + venetoclax in patients with acute myeloid leukemia

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

17/06/2026 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)

Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share

02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share

AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share

25/05/2026 – Following release of 2025 results and securing of clinical trial insurance policy, Maxim Group reiterates its buy recommendation on AB Science’s stock with a target price of EUR 4.0 per share

Annual financial results as of 31 December, 2025

13/05/2026 – AB Science reports its revenues for the year 2025 and provides an update on its activities

AB Science announces the successful completion of a EUR 3.2 million private placement

29/04/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors